New Drugs of Abuse and Withdrawal Syndromes.
New drugs of abuse continue to emerge, including synthetic cannabinoids, synthetic cathinones, and hallucinogens. It is important to recognize their individual psychopharmacologic properties, symptoms of intoxication, and symptoms of withdrawal. Providers must be vigilant of acute medical or psychiatric complications that may arise from use of these substances. Treatment of the patient also includes recognition of any substance use disorders as well as comorbid psychiatric disorders. Although pharmacologic treatments for substance use disorder (of the drugs included in this article) are limited, there are a variety of psychotherapeutic modalities that may be of some benefit.
Section of Emergency Medicine, Emergency Center, Baylor College of Medicine, 1504 Taub Loop, Houston, TX 77030, USA. Electronic address: andrabi.sara@gmail.com.
Sara
S
Andrabi
Section of Emergency Medicine, Emergency Center, Baylor College of Medicine, 1504 Taub Loop, Houston, TX 77030, USA.
Spencer
S
Greene
Nidal
N
Moukaddam
Stabilization, Treatment and Rehabilitation (STAR) Program for Psychosis, Menninger Department of Psychiatry, Baylor College of Medicine, 1504 Taub Loop, Houston, TX 77030, USA.
Nidal
N
Moukkadam
Menninger Department of Psychiatry, Harris Health System, Baylor College of Medicine, 1504 Taub Loop, Houston, TX 77030, USA.
Benjamin
B
Li
D015198:Designer Drugs; D006801:Humans; D011619:Psychotropic Drugs; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis*; D019966:Substance-Related Disorders / Q000175:diagnosis*
D015198:Designer Drugs; D011619:Psychotropic Drugs
Amphetamine; Drug abuse; Drug withdrawal; NBOMe; Synthetic cannabinoid